Redeye endorses the updated clinical guidelines in Japan supporting quantitative neuromuscular patient monitoring. In our initial report on Senzime, we emphasised that stronger clinical guidelines are an important driver for adoption and higher utilisation rates of the TetraGraph system. The updated Japanese guidelines strengthen this view, and we reiterate our valuation of the company.
LÄS MER
